Ratings Groupe Berkem

Equities

ALKEM

FR00140069V2

Market Closed - Euronext Paris Other stock markets 11:20:05 2024-06-04 am EDT			5-day change	1st Jan Change
2.34 ^EUR	+0.43%		-2.50%	-23.53%

May. 13	Groupe Berkem Unveils BiombalanceTM and Pineol Premium, Two Active Ingredients from Its New Nutraceutical Range	CI
Apr. 30	Groupe Berkem Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Strengths

Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

The company sustains low margins.
The group shows a rather high level of debt in proportion to its EBITDA.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
GROUPE BERKEM	-23.53%	44.63M	-
ELI LILLY AND COMPANY	+42.83%	748B	C+
NOVO NORDISK A/S	+34.11%	598B	B
JOHNSON & JOHNSON	-5.70%	356B	C+
MERCK & CO., INC.	+18.06%	325B	B-
ABBVIE INC.	+4.63%	283B	C+
ASTRAZENECA PLC	+17.02%	245B	B+
NOVARTIS AG	+9.26%	211B	B-
ROCHE HOLDING AG	-4.21%	209B	A+
PFIZER, INC.	+2.43%	166B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes